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Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, IsraelAssessment of tumor down-staging in patients with hepato-
cellular carcinoma and elevated alpha-fetoprotein (AFP) who
are candidates for liver transplantation: is it too early to
mourn the demise of AFP?
AFP was ﬁrst described by Abelev et al. in the early 1960s [1,2].
Over the next 30 years, and before the introduction of modern
imaging techniques, AFP measurement was frequently used for
screening of patients at risk, conﬁrmation of diagnosis of hepato-
cellular carcinoma (HCC), and even surveillance. However, in the
past decade, it became progressively clear that serum AFP mea-
surements do not correlate reliably with tumor size, stage, and
prognosis in HCC [3]. At a cutoff of 20 lg/ml, AFP has a 60% sen-
sitivity and 91% speciﬁcity as a diagnostic tool for HCC with posi-
tive and negative predictive values of 25% and 98%, respectively
(at an HCC prevalence of 5%) [4]. These data lead to a 2001 Edito-
rial published in this Journal by M. Sherman entitled: ‘‘Alpha-feto
protein: an obituary’’, who suggested ‘‘bidding a fond adieu to
AFP as a test for diagnosis and surveillance of HCC’’ [5]. Conse-
quently, the recent AASLD guidelines for the management of
HCC adopted this policy verbatim and excluded the recommen-
dation for testing and monitoring of AFP levels for diagnosis
and surveillance of HCC in patients at risk [6]. Despite these res-
ervations, many clinicians still check AFP in their routine clinical
practice, knowing that markedly elevated AFP levels are a poor
prognostic sign in HCC.
Therefore, at present, AFP testing remains at best only a con-
ﬁrmatory test in patients with a liver mass detected by an up to
date imaging technique. However, even then, it cannot be used as
an absolute diagnostic biologic marker for HCC, due to the differ-
ential diagnosis suggested by such a ﬁnding.
In the present issue of the Journal, Merani and co-workers pro-
vide evidence supporting a new application for AFP testing [7].
They propose to use AFP monitoring in those HCC patients who
secrete AFP, for prediction of outcome in HCC candidates for liver
transplantation (LT). Special emphasis is given to forecasting
prognosis in patients who underwent a pre-transplant down-
staging procedure (mainly ablation), provided the last AFP mea-
surement is determined close to LT. The Canadian and Swiss
investigators used the US Scientiﬁc Registry of Transplant Recip-
ients database of 6817 HCC listed patients between 2003 and mid
2009. Intent to treat (ITT) analysis included evaluation of AFP and
total tumor volume (TTV) at time of listing and at time of trans-
plantation, expressed also as AFP and TTV velocity. Serum AFPJournal of Hepatology 20
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on current guidelines, almost all patients fulﬁlled the Milan crite-
ria and 35.5% of 5481 patients with available information under-
went a pre-LT ablation procedure, while 59% did not receive any
anti-tumor therapy. The main results of this interesting study
indicate that HCC patients with initial AFP levels >400 ng/ml at
listing, in whom loco-regional therapy led to a drop in AFP levels
<400 ng/ml, had better survival as compared to patients failing to
reduce AFP. Speciﬁcally, overall ITT survival from listing in
patients downstaged to AFP levels <400 ng/ml compared to
patients with AFP >400 ng/ml was 81% vs. 48%, respectively, at
3 years post LT. The authors suggest that AFP monitoring in
HCC transplant candidates (with special emphasis on treatment
response in those patients with AFP >400 ng/ml) may be used
as a new tool for assessment of prognosis in patients undergoing
pre-transplant loco-regional ablation therapy.
This report adds new fuel to the currently ongoing debate
concerning extension of the referral rules for LT in HCC patients
beyond the Milan criteria, as previously suggested by several
investigators [8–11]. On the one hand, it seems that referral for
LT of successfully downstaged patients may be an acceptable
solution for a new subgroup of HCC patients with a similar pre-
dictable outcome as compared to LT candidates within the Milan
criteria. Such an approach based on the presented data, seems
logic for patients in whom downstaging by loco-regional treat-
ment is indeed conﬁrmed by suppression of AFP <400 ng/ml
and obviously also by imaging studies. On the other hand, incor-
poration of new rules into currently accepted guidelines may
augment the already congested waiting lists worldwide for
patients awaiting LT and indirectly contribute to further exten-
sion of the waiting time for non-HCC candidates for LT.
The report of Merani et al. has a number of limitations includ-
ing its retrospective evaluation and the fact that only 9% of
surveyed patients had hepatitis B derived chronic liver disease,
which is much more prevalent in Africa and Asia. Furthermore,
in the present study, the cut-off level for statistical analysis of
successful down staging was arbitrarily set at an AFP level
of 400 ng/ml. It appears that at this threshold, assessment of
successful down staging through monitoring of falling AFP levels
(in addition to imaging follow-up) is relatively reproducible.
However, it is not known whether this threshold is indeed ﬁxed
or ﬂexible along a wider range of AFP levels. Finally, almost the
entire study cohort was listed according to the Milan criteria.
Consequently, the studied population does not necessarily
represent the target population for down-staging beyond the
Milan criteria. Repeating this analysis in an independent cohort
of down-staged HCC patients beyond the Milan criteria to be11 vol. 55 j 741–742
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studied prospectively, will require a very large sample size and is
not foreseen in the near future.
Thus, despite some limitations, this report, based on informa-
tion extracted from a large database, provides evidence for a
proof of principle as well as a wealth of details on the role and
effects of down-staging in patients with HCC. This information
is therefore an important addition to the limited available data
to support extension of selection criteria beyond Milan and
should be the focus of future discussion of this ‘‘hot’’ topic. Thus,
until the identiﬁcation of a better biologic marker for HCC, it
seems pre-mature to kiss goodbye to AFP in this selected group
of patients with HCC.Conﬂict of interest
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